Literature DB >> 17400339

The development of standardized case definitions and guidelines for adverse events following immunization.

Katrin S Kohl, Jane Gidudu, Jan Bonhoeffer, M Miles Braun, Michael Buettcher, Robert T Chen, Bakary Drammeh, Philippe Duclos, Harald Heijbel, Ulrich Heininger, Erik Hummelman, Thomas Jefferson, Brigitte Keller-Stanislawski, Elisabeth Loupi, S Michael Marcy.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17400339     DOI： 10.1016/j.vaccine.2007.02.063

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  18 in total

1.  Overcoming Barriers and Identifying Opportunities for Developing Maternal Immunizations: Recommendations From the National Vaccine Advisory Committee.

Authors: 
Journal:  Public Health Rep       Date:  2017-04-05       Impact factor: 2.792

2.  Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.

Authors:  Huakun Lv; Xuejiao Pan; Hui Liang; Ying Wang; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-09-07       Impact factor: 4.526

3.  Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework.

Authors:  Françoise Renaud; Lynne M Mofenson; Charlotte Bakker; Helen Dolk; Valeriane Leroy; Angelina Namiba; Leyla Sahin; Roger Shapiro; Amy Slogrove; Claire Thorne; Marissa Vicari; Daniel Low-Beer; Meg Doherty
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

4.  Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children.

Authors:  Amy L Slogrove; Barbara Burmen; Mary Ann Davies; Andrew Edmonds; Elaine J Abrams; Ellen G Chadwick; Tessa Goetghebuer; Lynne M Mofenson; Mary E Paul; Claire Thorne; Paige L Williams; Marissa Vicari; Kathleen M Powis
Journal:  Clin Infect Dis       Date:  2022-08-25       Impact factor: 20.999

5.  Template protocol for clinical trials investigating vaccines--focus on safety elements.

Authors:  Jan Bonhoeffer; Egeruan B Imoukhuede; Grace Aldrovandi; Novilia S Bachtiar; Eng-Soon Chan; Soju Chang; Robert T Chen; Rohini Fernandopulle; Karen L Goldenthal; James D Heffelfinger; Shah Hossain; Indira Jevaji; Ali Khamesipour; Sonali Kochhar; Mamodikoe Makhene; Elissa Malkin; David Nalin; Rebecca Prevots; Ranjan Ramasamy; Sarah Sellers; Johan Vekemans; Kenneth B Walker; Pam Wilson; Virginia Wong; Khalequz Zaman; Ulrich Heininger
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

6.  Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.

Authors:  Daniel N A Ankrah; Aukje K Mantel-Teeuwisse; Marie L De Bruin; Philip K Amoo; Charles N Ofei-Palm; Irene Agyepong; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

7.  Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  Mark D Gershman; J Erin Staples; Adwoa D Bentsi-Enchill; J Gabrielle Breugelmans; Glacus S Brito; Luiz Antonio Bastos Camacho; Pascale Cottin; Cristina Domingo; Anna Durbin; Joaquim Gascon; Fouzia Guenaneche; Edward B Hayes; Zsuzsanna Jelenik; Alena Khromava; Reinaldo de Menezes Martins; Mario Masana Wilson; Nathalie Massy; Abdulsalami Nasidi; Matthias Niedrig; Adam Sherwat; Theodore Tsai; Anna Vilella; Mary Elizabeth Wilson; Katrin S Kohl
Journal:  Vaccine       Date:  2012-05-04       Impact factor: 3.641

8.  Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Authors:  Malini DeSilva; Flor M Munoz; Mark Mcmillan; Alison Tse Kawai; Helen Marshall; Kristine K Macartney; Jyoti Joshi; Martina Oneko; Annette Elliott Rose; Helen Dolk; Francesco Trotta; Hans Spiegel; Sylvie Tomczyk; Anju Shrestha; Sonali Kochhar; Elyse O Kharbanda
Journal:  Vaccine       Date:  2016-07-18       Impact factor: 3.641

9.  Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data.

Authors:  Elizabeth N Allen; Clare I R Chandler; Nyaradzo Mandimika; Cheryl Pace; Ushma Mehta; Karen I Barnes
Journal:  Malar J       Date:  2013-09-16       Impact factor: 2.979

10.  Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.

Authors:  Jayani Pathirana; Flor M Muñoz; Victoria Abbing-Karahagopian; Niranjan Bhat; Tara Harris; Ambujam Kapoor; Daniel L Keene; Alexandra Mangili; Michael A Padula; Stephen L Pande; Vitali Pool; Farshad Pourmalek; Frederick Varricchio; Sonali Kochhar; Clare L Cutland
Journal:  Vaccine       Date:  2016-07-19       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.